Compare BLTE & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLTE | ADMA |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.1B |
| IPO Year | 2022 | N/A |
| Metric | BLTE | ADMA |
|---|---|---|
| Price | $148.92 | $19.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $149.00 | $28.50 |
| AVG Volume (30 Days) | 244.0K | ★ 3.2M |
| Earning Date | 11-10-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 205.35 |
| EPS | N/A | ★ 0.86 |
| Revenue | N/A | ★ $488,559,000.00 |
| Revenue This Year | N/A | $22.19 |
| Revenue Next Year | N/A | $24.33 |
| P/E Ratio | ★ N/A | $23.13 |
| Revenue Growth | N/A | ★ 27.63 |
| 52 Week Low | $49.00 | $13.50 |
| 52 Week High | $160.55 | $25.67 |
| Indicator | BLTE | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 68.29 | 71.19 |
| Support Level | $140.07 | $19.13 |
| Resistance Level | $154.00 | $20.22 |
| Average True Range (ATR) | 12.43 | 0.79 |
| MACD | 0.74 | 0.15 |
| Stochastic Oscillator | 78.20 | 91.28 |
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.